What is the Study?
Multicenter, randomized, double-blind, placebo-controlled, parallel-group two year study to evaluate the effect of subcutaneous Gantenerumab (RO4909832) on cognition and function in prodromal Alzheimer's disease. Study Number: WN25203.
What is the Purpose of Gantenerumab?
We hope to learn about the effects of a new drug called 'gantenerumab'. Gantenerumab is an investigational drug being studied by Roche. We are interested to know its effect on how fast symptoms get worse in people who may be in the early stages of Alzheimer's disease. This stage of the disease is also called 'prodromal' Alzheimer's disease.
The population will consist of persons age 50-85 with prodromal (mild cognitive impairment) Alzheimer's disease. Additional study criteria will be reviewed with patient and caregiver prior to enrolling into study.
If you are interested in learning more about the Gantenerumab study, please call (401) 455-6403 or send an e-mail to: firstname.lastname@example.org.
For information on other current research studies at Butler Hospital please click here.